Immunotherapy for the Treatment of Breast Cancer Guideline Overview: CE Information

Joint Accreditation Statement

2a19d2b0cf06454497be6a903e0a56c3.pngIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.   

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-3082-L01-P

Type of Activity: Knowledge

Hardware/Software Requirements
The webinar is accessed through Zoom. An internet connection and the system requirements are needed to access the webinar.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Target Audience

Practicing clinicians with limited experience in the use of immunotherapy are the target audience for this live introductory webinar. Other caregivers such as nurses, oncology pharmacists, and other advanced practice providers may also benefit.

Educational Objectives

Upon completion of this program, participants will be able to:

  • Select appropriate diagnostics and biomarker testing tailored to the clinical setting for a patient being considered for immunotherapy based on the expert panel recommendations in the SITC Clinical Practice Guideline (CPG)
  • Implement immunotherapy treatments effectively and appropriately for breast cancer according to the recommendations in the CPG
  • Appraise patterns of response to immunotherapy in order to appropriately monitor and manage patients during treatment

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer